Amarin Corp Plc (AMRN)

[JRoon71]

Sleven, I'm not saying there's no overlap. There is. I agree with that. I'm saying, procedurally, that the court decision in Amarin vs. Hikma only binds Hikma, but cannot automatically enjoin the other generics. It would then require Amarin to sue them.

Although, in the meantime, Amarin could pursue injunctions against the other generics, which I think they would have a very strong argument for, assuming the court agrees with the overlapping indication argument. Or, if the court rules in this way, I would think the generics would feel strong pressure to withdraw.

We just have to hope that, if we win, the court rules in such a way that it puts substantial pressure on the other generics, and does not simply mandate "better labeling" (but allows them to continue marketing generic IPE).